Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations a randomized clinical trial

JAMA Neurology

Volumn 74, Issue 2, 2017, Pages 216-224

  Schapira, Anthony H V ^a   Fox, Susan H ^b   Hauser, Robert A ^c   Jankovic, Joseph ^d   Jost, Wolfgang H ^e   Kenney, Christopher ^f   Kulisevsky, Jaime ^g   Pahwa, Rajesh ^h   Poewe, Werner ⁱ   Anand, Ravi ^j  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e Parkinson Klinik   (Germany)

^f Biotie Therapies   (United States)

^g UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^h UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

ⁱ INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^j APC   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BENSERAZIDE; CARBIDOPA; LEVODOPA; PLACEBO; SAFINAMIDE; ALANINE; ANTIPARKINSON AGENT; BENZYLAMINE DERIVATIVE;

ADJUVANT THERAPY; ADULT; AGED; ANXIETY; ARTHRALGIA; ARTICLE; BACKACHE; BRADYKINESIA; CAUCASIAN; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSKINESIA; DYSPEPSIA; FATIGUE; FEMALE; HALLUCINATION; HEADACHE; HUMAN; HYPERTENSION; HYPESTHESIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MOTOR FLUCTUATION; MULTICENTER STUDY; MUSCLE SPASM; NAUSEA; PARALLEL DESIGN; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RIGIDITY; SCREENING; SIDE EFFECT; SOMNOLENCE; UPPER ABDOMINAL PAIN; URINARY TRACT INFECTION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; FOLLOW UP; INTERNATIONAL COOPERATION; MIDDLE AGED; MOTOR ACTIVITY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALANINE; ANTIPARKINSON AGENTS; BENZYLAMINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL COOPERATION; LEVODOPA; MALE; MIDDLE AGED; MOTOR ACTIVITY; OUTCOME ASSESSMENT (HEALTH CARE); PARKINSON DISEASE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 85014652761     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2016.4467     Document Type: Article

References (21)

1. Schapira AH, Emre M, Jenner P, PoeweW. Levodopa in the treatment of Parkinson's disease. Eur J Neurol. 2009;16(9):982-989.
2. Ferreira JJ, Katzenschlager R, Bloem BR, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur J Neurol. 2013;20(1):5-15.
3. Obeso JA, Olanow CW, Nutt JG. Levodopa motor complications in Parkinson's disease. Trends Neurosci. 2000;23(10)(suppl):S2-S7.
4. Warren Olanow C, Kieburtz K, Rascol O, et al.; Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE-PD) Investigators. Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson's disease. Mov Disord. 2013;28(8):1064-1071.
5. Marzo A, Dal Bo L, Monti NC, et al. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. Pharmacol Res. 2004;50(1):77-85.
6. Onofrj M, Bonanni L, Thomas A. An expert opinion on safinamide in Parkinson's disease. Expert Opin Investig Drugs. 2008;17(7):1115-1125.
7. Schapira AH. Safinamide in the treatment of Parkinson's disease. Expert Opin Pharmacother. 2010;11(13):2261-2268.
8. Caccia C, Maj R, Calabresi M, et al. Safinamide: From molecular targets to a new anti-Parkinson drug. Neurology. 2006;67(7)(suppl 2):S18-S23.
9. Stocchi F, Arnold G, Onofrj M, et al.; Safinamide Parkinson's Study Group. Improvement of motor function in early Parkinson disease by safinamide. Neurology. 2004;63(4):746-748.
10. Stocchi F, Vacca L, Grassini P, et al. Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition. Neurology. 2006;67(7) (suppl 2):S24-S29.
11. Stocchi F, Borgohain R, Onofrj M, et al.; Study 015 Investigators. A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients. Mov Disord. 2012;27(1):106-112.
12. World Medical Association. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194. doi:10 .1001/jama.2013.281053
13. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Guidance for Industry-E6 Good Clinical Practice: Consolidated Guidelines. http://www.ich.org/products/guidelines /efficacy/article/efficacy-guidelines.html. Accessed November 11, 2016.
14. Hauser RA, Friedlander J, Zesiewicz TA, et al. A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin Neuropharmacol. 2000;23(2): 75-81.
15. Medical Dictionary for Regulatory Activities. http: //www.meddra.org/. Accessed May 5, 2016.
16. Weintraub D, Hoops S, Shea JA, et al. Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease. Mov Disord. 2009; 24(10):1461-1467.
17. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: The PRESTO study. Arch Neurol. 2005;62(2):241-248.
18. Rascol O, Brooks DJ, Melamed E, et al.; LARGO study group. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): A randomised, double-blind, parallel-group trial. Lancet. 2005;365(9463):947-954.
19. Borgohain R, Szasz J, Stanzione P, et al.; Study 016 Investigators. Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations. Mov Disord. 2014;29(2):229-237.
20. Borgohain R, Szasz J, Stanzione P, et al.; Study 018 Investigators. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease. Mov Disord. 2014;29(10):1273-1280.
21. Gregoire L, Jourdain VA, Townsend M, Roach A, Di Paolo T. Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys. Parkinsonism Relat Disord. 2013;19(5):508-514.